Funded Grants

Back to results

A Randomized Controlled Trial of Pimozide in Subjects with ALS

Project Overview

This project is a Phase II study involving 100 participants across 8 ALS clinics across Canada. The trial, led by the Principal Investigator of the Canadian Neuromuscular Disease Registry (CNDR) and the Chair of the Canadian ALS Research Network (CALS) will examine whether pimozide, a drug already approved by Health Canada for use in psychoses like schizophrenia and Tourette’s syndrome, might slow progression of ALS. Pimozide is particularly effective at stabilizing neuromuscular function, which means it can strengthen the connection where the motor neuron meets the muscle (called the neuromuscular junction or NMJ). It is hoped that by strengthening this connection, there will be preservation of transmission of signals from the brain to the muscle and slowing of paralysis in ALS. The project also involves the validation of an exciting new potential biomarker. Biomarkers are ways of monitoring the body (eg. looking for something in blood or doing a particular physical examination) to either diagnose ALS earlier, select individuals for a trial or monitor effectiveness of a treatment.

 

Principal Investigator

Lawrence Korngut , University of Calgary

Partners and Donors

ALS Society of Canada

Project Ongoing

A Randomized Controlled Trial of Pimozide in Subjects with ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Arthur J. Hudson Translational Team Grant

  • Province

    Alberta

  • Start Date

    2016

  • Total Grant Amount

    $489,856

  • Health Canada Contribution

    $244,928